Rilzabrutinib ITP denied due to quantity / dose limits by Cigna?
Quantity-limit denials usually flip when the appeal documents the clinically appropriate dose for the patient's weight, kidney function, or escalation schedule, citing the FDA label or specialty-society guideline.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for rilzabrutinib itp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on Rilzabrutinib ITP
## Why Cigna Applies Quantity Limits to Rilzabrutinib for ITP
Quantity limits (QL) are utilization-management rules that cap how much of a drug Cigna will cover in a given period — typically expressed as a maximum number of units, tablets, or fills per month. For rilzabrutinib in ITP, a quantity-limit denial means the prescription as written exceeds that cap. This may happen when a prescriber writes for a dose or supply that differs from what Cigna's policy anticipates, or when a patient requires a quantity outside the standard range for reasons specific to their clinical situation.
## Why This Denial Is Appealable
Quantity limits are applied at a population level and cannot account for individual patient needs. When a patient's clinical circumstances require a quantity above the standard limit, the insurer is required to consider a quantity-limit exception. Refusing to do so without reviewing the medical record is a failure of the required full-and-fair review.
Federal appeal rights: - ACA §2719 / ERISA §503 require a written internal appeal decision with clinical rationale. - External review by an independent review organization is available after internal denial; the window is generally up to approximately four months from the denial — verify the exact date on your Explanation of Benefits. - Expedited review is available where delay would jeopardize health.
## Your Appeal Process and Timeline
1. Request Cigna's quantity-limit exception criteria in writing. 2. Have your prescriber prepare a letter explaining precisely why the prescribed quantity is clinically necessary for your specific situation, referencing the FDA-approved prescribing information for rilzabrutinib and the applicable ASH guideline. 3. File the internal appeal with the supporting documentation. 4. Request external review if the internal appeal fails.
## Documentation to Gather
- Prescriber letter on quantity: a specific explanation of why the prescribed amount is medically necessary, tied to your clinical presentation — not generic.
- FDA prescribing information: the dosing section of the current label, showing the approved dosing range and any guidance on dose adjustment.
- Clinical records: chart notes documenting the severity of ITP, platelet levels over time, and treatment response that supports the prescribed quantity.
- Prior-treatment history: showing the clinical journey that led to this drug and this dose.
## Criteria-Mapping Structure
Review the FDA label dosing section and Cigna's quantity-limit policy side by side. For each limit Cigna has set, document the clinical basis for the prescribed quantity. If the prescribed amount falls within the FDA-approved dosing range, state that explicitly. If the clinical situation requires individualized dosing, the prescriber's letter should explain why standard quantity assumptions do not apply to this patient.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →